Actively Recruiting
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Led by University of Washington · Updated on 2026-04-17
2000
Participants Needed
1
Research Sites
417 weeks
Total Duration
On this page
Sponsors
U
University of Washington
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.
CONDITIONS
Official Title
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have or have had ovarian, peritoneal, or fallopian tube carcinoma with a life expectancy of greater than 6 months
- Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy
- Have or have had a solid tumor diagnosis with either at least 4 months of exposure to a PARP inhibitor or a diagnosis of a blood disorder including clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm
You will not qualify if you...
- Life expectancy less than 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109
Actively Recruiting
Research Team
S
Swisher Lab Research Coordinators
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here